• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

April 26, 2019

View Archived Issues

'ASK1'ng to be written off? Gilead's selonsertib fails another phase III NASH trial

Once hailed by former Gilead Sciences Inc. CEO and President John Milligan as "the beginning of a very important NASH franchise," the oral apoptosis signal-regulating kinase 1 (ASK1) inhibitor selonsertib has again failed to meet the primary endpoint in a phase III trial. Top-line results of the Stellar-3 study for patients with bridging fibrosis due to nonalcoholic steatohepatitis (NASH) did not meet the prespecified week 48 primary endpoint of a ≥ 1-stage histologic improvement in fibrosis without worsening of the condition after failing to meet a similar endpoint for NASH patients with compensated cirrhosis in Stellar-4. Read More

'Win-win' merger combines Mateon, Oncotelic pipelines

Mateon Therapeutics Inc. and Oncotelic Inc. completed the merger they announced on April 17. Oncotelic becomes a wholly owned subsidiary of Mateon, and the combined company has a pipeline of TGF-beta RNA therapeutics for late-stage cancers, including gliomas, pancreatic cancer and melanoma. Read More

SK Biopharm, Twoxar combine AI technologies in discovery bid for lung cancer candidates

HONG KONG – SK Biopharmaceuticals Co. Ltd., a spin-off from Korean conglomerate SK Holdings Co. Ltd., inked a joint research agreement with Twoxar Inc., a U.S.-based artificial intelligence (AI)-driven biopharma, to discover and develop drugs for non-small-cell lung cancer (NSCLC). Read More

After a slow start, biopharma company IPOs pick up speed in Q1

The U.S. government shutdown was a contributing factor why no biopharma companies graduated to the public ranks in January. However, it was a hectic period after that, with a total of 11 companies completing their IPOs in the U.S. by the end of the first quarter, collectively raising about $1.07 billion. That figure was down 10.3% from the $1.2 billion raised by 14 companies listing on U.S. exchanges in the first quarter last year. Read More

Oncotype DX could save $50M per year, allow 70% of breast cancer patients to skip chemo

A new study by the Georgetown Lombardi Comprehensive Cancer Center and the National Cancer Institute indicates that Oncotype DX-guided treatment could cut the cost of first year breast cancer care in the U.S. by $50 million. JNCI published the results of the study on Wednesday. Genomic Health Inc. of Redwood City, Calif., produces Oncotype DX. Read More

A decade of incentives to promote antibiotic development and still no viable route to commercial success

It should be motoring to profitability, but nine months after the U.S. launch of its new antibiotic, Zemdri (plazomicin), Achaogen Inc. has filed for Chapter 11 bankruptcy and is now selling off its assets. There can be no more potent illustration of the mismatch between antibiotics and market forces, nor of how despite numerous measures to incentivize antibiotic discovery and development, the system isn't working. Read More

Regulatory front

Astellas Pharma U.S. Inc., of Northbrook, Ill., and Amgen Inc., of Thousand Oaks, Calif., Thursday became the latest biopharma companies making settlements with the U.S. Department of Justice (DoJ) to resolve allegations that they illegally paid the Medicare copays for their drugs through purportedly independent foundations, thus violating the anti-kickback law. Read More

Earnings

Alexion Pharmaceuticals Inc., of New Haven, Conn., reported first-quarter revenues of $1.14 billion, a 23% year-over-year increase, as compared to consensus estimates of about $1.1 billion, with non-GAAP earnings per share of $2.39, a 42% year-over-year increase, vs. estimates of $2.20.  Read More

Financings

Navan Technologies Inc., of South San Francisco, said it closed a seed investment round led by Amgen Ventures, High-Tech Gründerfonds, Hemi Ventures and other institutional and private investors. Navan is developing cell and gene therapies using its nonviral Nanostraw platform based on technology licensed from Stanford University.  Read More

Other news to note

Zymeworks Inc., of Vancouver, British Columbia, said Daiichi Sankyo Co. Ltd., of Tokyo, exercised its option for a commercial license to an immuno-oncology bispecific built on Zymeworks' Azymetric and Efect platforms. Zymeworks said it expects to receive a $3.5 million milestone payment based on Daiichi Sankyo's selection of the first of up to three lead candidates under collaboration agreements between the companies. Read More

Clinical data for April 25, 2019

Read More

Regulatory actions for April 25, 2019

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 11, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 10, 2025.
  • Enflonsia

    Merck wins FDA approval in pediatric RSV and steps into CDC uncertainty

    BioWorld
    With the U.S. FDA’s approval of Enflonsia (cesrovimab) to prevent respiratory syncytial virus (RSV) infection lower respiratory tract disease in newborns and...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 10, 2025
  • Red blood cells in an artery with cholesterol

    In two phase IIIs, Merck’s PCSK9 inhibitor cuts cholesterol

    BioWorld
    In two phase III studies, Merck & Co. Inc.’s oral, once monthly proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor produced statistically significant...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe